Abstract 68P
Background
Luminal A (ER+/ HER2-low) is the most common breast cancer subtype and hormonal therapy is the preferred first-line treatment. However, most patients (>50%) develop resistance, leading to disease recurrence and limited clinical benefit, even with the addition of a combination regimen. Therefore, treatment optimization is required urgently. Furthermore, studies have indicated that the tumours with low HER2 and ER levels evade ER blockade via the upregulation of EGFR/HER2 signalling. Therefore, this study will aim to assess the effects of anti-HER2 in combination with hormone treatment in ER+/HER2-low breast cancer.
Methods
A panel of patient-derived organoids ( n=31) was successfully established and characterized using immunohistochemical and confocal imaging. Through the drug sensitivity test, the drug combination efficacy of the anti-HER2 drug (neratinib), hormone treatment (fulvestrant), and CDK4/6 inhibitor (palbociclib) was tested in HER2-low breast cancer patient-derived organoids. The underlying molecular mechanisms were investigated using immunofluorescence, western blot analysis, immunohistochemical staining, and cell cycle analysis.
Results
We found that neratinib combined with palbociclib and or fulvestrant showed better efficacy than palbociclib and fulvestrant combination in HER2-low breast cancer, resulting in the deactivation of HER2-EGFR signalling pathway, decreased transcriptional activation of ER and cycle proteins. Furthermore, the dual or triple combination of neratinib, palbociclib, and fulvestrant could decrease the nuclear translocation of ER. This may be the underlying mechanism by which the addition of palbociclib and/or fulvestrant to neratinib was more beneficial than the combination of palbociclib plus fulvestrant.
Conclusions
Our study provides the rationale for combining neratinib with fulvestrant and or palbociclib for the treatment of ER+/HER2-low breast cancer and indicates that the dual or triple combination treatment may be a better strategy to overcome resistance to hormone treatment. Moreover, future translational research will investigate the potential biomarkers indicating the responsiveness to the treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Puma biotechnology.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract